Trials / Completed
CompletedNCT03166891
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multi-site, Exploratory Study
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Chipscreen Biosciences, Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib(50mg，QD，PO) works in treating patients with relapsed or refractory ovarian cancer, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
Detailed description
The purpose of this study is to assess the efficacy and safety include adverse events, vital signs, laboratory tests ,etc., of Chiauranib in ovarian cancer patients due to the outcomes of the phase I study, and to explore the relevance between the latent biomarkers of Chiauranib and clinical benefit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chiauranib | Take 50mg orally once daily |
Timeline
- Start date
- 2017-12-15
- Primary completion
- 2019-03-20
- Completion
- 2019-03-20
- First posted
- 2017-05-25
- Last updated
- 2020-01-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03166891. Inclusion in this directory is not an endorsement.